The clinical benefits of [18F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [18F]FDG PET/CT

The clinical benefits of [18F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [18F]FDG PET/CT

Abstract Background Accurate clinical TNM staging is crucial for managing GEP-NENs according to the latest NCCN guidelines. [68Ga] labeled somatostatin receptor (SSTR) PET/CT outperforms [18F]FDG PET/CT in evaluating well and moderately differentiated NENs. However, few studies have investigated the...

Full description

Saved in:
Bibliographic Details
Main Authors: Donghe Chen, Zhenfeng Liu, Guolin Wang, Mengjiao Tu, Fei Yang, Chunting Jiang, Kui Zhao, Xinhui Su
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Medical Imaging
Subjects:
Neuroendocrine neoplasms
GEP-NENs
[18F]FDG
[18F]OC
PET/CT
SUVmax
Online Access:https://doi.org/10.1186/s12880-025-01824-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12880-025-01824-9

Similar Items